
    
      Subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio
      for a period of 12 weeks. Subjects who complete the 12 week treatment period and are eligible
      may continue to the open label extension phase which will last 2 years.
    
  